Pharmaceutical Technology on MSN2d
FDA awards ODD status to Sanofi’s rilzabrutinib for two rare conditionsSanofi's oral, reversible Bruton’s tyrosine kinase (BTK) inhibitor rilzabrutinib has gained US Food and Drug Administration ...
Zacks Investment Research on MSN3d
SNY's Rilzabrutinib Gets FDA's Orphan Drug Tag for Two Rare DiseasesSanofi SNY announced that the FDA has granted orphan drug designation to its investigational BTK inhibitor, rilzabrutinib, ...
The FDA has granted orphan drug designation to rilzabrutinib for IgG4-related disease and warm autoimmune hemolytic anemia, ...
Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicinesDesignation granted for warm autoimmune ...
Sanofi's rilzabrutinib receives FDA orphan drug designation for two rare diseases. Clinical studies show meaningful response ...
Paris: Sanofi has announced that the US Food and Drug Administration (FDA) has granted orphan drug designation to ...
Sanofi's oral, reversible Bruton’s tyrosine kinase (BTK) inhibitor rilzabrutinib has gained US Food and Drug Administration (FDA) orphan drug designation (ODD) to treat two rare conditions ...
Rilzabrutinib is currently under regulatory review in the US, EU and China for potential use in immune thrombocytopenia Paris, April 3, 2025. The US Food and Drug Administration (FDA) has granted ...
Designation granted for warm autoimmune hemolytic anemia and IgG4-related disease Rilzabrutinib is currently under regulatory review in the US, EU and China for potential use in immune ...
Designation granted for warm autoimmune hemolytic anemia and IgG4-related disease Rilzabrutinib is currently under regulatory review in the US, EU and China for potential use in immune ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback